---
title: "Schizophrenia Models"
canonical: "https://www.pharmalegacy.com/indications/cns-disease-models/neuropsychiatric-diseases/schizophrenia/"
lastmod: "2026-07-13T09:28:53+00:00"
generator: "llm-mirrors/1.0.19"
---

# PRECLINICAL SCHIZOPHRENIA STUDIES

PHARMALEGACY HAS THE EXPERTISE AND MODELS YOU NEED TO ADVANCE YOUR SCHIZOPHRENIA PROGRAM.

✕

Let PharmaLegacy provide the answers you need.

MODELS / SERVICES

MK-801-induced schizophrenia model in mouse ▼

Case Study - MK-801-induced schizophrenia model in mouse & Endpoint Measurements

Schizophrenia is a severe psychiatric disorder affecting approximately 1% of the general population, characterized by a constellation of positive, cognitive and negative symptoms. For preclinical animal research, investigators have established multiple modeling strategies including pharmacological manipulation, neurodevelopmental disruption, neurotoxic insult and transgenic modification to recapitulate behavioral alterations recapitulating core schizophrenia-related phenotypes, such as hyperlocomotion.
At PharmaLegacy, we have developed an MK-801-induced mouse model to mimic the positive symptoms of schizophrenia. Spontaneous locomotor activity assays are adopted to validate the construct validity of this MK-801-driven schizophrenia model and evaluate the therapeutic efficacy of the reference drug Haloperidol. This platform lays a robust foundation for the pharmacodynamic assessment of novel drug candidates targeting schizophrenia in future research.
PharmaLegacy has completed the pharmacodynamic evaluation of xanomeline as a positive control drug against positive symptoms in the MK-801-induced schizophrenia mouse model. The results demonstrate that xanomeline significantly reverses MK-801-triggered hyperlocomotion in animals.

Haloperidol Reference Drug (Open Field Test)

Xanomeline Efficacy (Open Field Test)

PCP-induced schizophrenia model in mouse

Ketamine-induced schizophrenia model in mouse

Amphetamine-induced hyperactivity in cynomolgus monkey

PharmaLegacy’s operational advantages:

1500+ validated animal models of disease spanning 100+ indications
30,000+ animal capacity
Staffing and facilities to run 200+ concurrent studies
380,000 square feet of facilities
Ability to start most studies in under 2 weeks

PharmaLegacy has the capability and capacity to advance your schizophrenia pipeline. Contact us today.

✕

Let PharmaLegacy provide the answers you need.

We’re ready when you are.             Tell us your Schizophrenia pipeline challenges.

+86-21-6176-5100*8051
+1-617-803-9415

info@pharmalegacy.com

✕

Csv Download